echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Sub-Journal of Nature: These strategies can be used to improve immune checkpoint inhibitors

    Sub-Journal of Nature: These strategies can be used to improve immune checkpoint inhibitors

    • Last Update: 2021-03-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    As an immunosuppressive pathway, immune checkpoints are essential for maintaining autoimmune tolerance and regulating the duration and scope of immune responses in peripheral tissues.


    On the other hand, due to the heterogeneity of tumors and the complexity of the tumor microenvironment (TME), the overall effective rate of immune checkpoint inhibitor therapy is low, and there is still room for improvement in many areas.


    The entry of T cells into specific tissue sites involves complex signaling pathways between numerous cell types and soluble factors.


    In terms of tumor vasculature, combination therapies targeting vascular endothelial cell growth factor (VEGF) or VEGF receptor (VEGFR) and PD-1, PDL-1 or PDL-2 are under evaluation, some of which are approved for clinical use treatment.


    In addition to VEGF, the pro-angiogenic factor B-type endothelin receptor (ETBR) is another potential target for immune checkpoint inhibitor combination therapy.


    Chemokines and cytokines are another focus of attention of researchers.


    Even if T cells pass through many "obstacles" and finally enter TME, there are still many cytokines in TME, which can induce T cell failure and dysfunction.


    The mononuclear phagocytic system (MPS) includes monocytes, macrophages and dendritic cells.


    Take ALX Oncology’s research product ALX148 as an example.


    We hope that more immune checkpoint inhibitors will come out soon and benefit more patients around the world.


    Reference materials:

    [1] Kubli, SP, Berger, T.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.